 TEL AVIV, Israel, March 18, 2021 PRNewswire -- Galmed Pharmaceuticals Ltd. Nasdaq: GLMD Galmed or the Company, a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator AramcholTM, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and fibrosis, reports financial results for the three and twelve months ended December 31, 2020. 